Measles, Mumps, and Rubella (MMR) Vaccine
Treatment for Measles
Typical Dosage: 0.5 mL subcutaneous injection
Effectiveness
97%
Safety Score
75%
Clinical Trials
69
Participants
10M
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
75
DangerousModerateSafe
Treatment Details
Dosage Range
0.5 mL subcutaneous injection
Time to Effect
2-4 weeks for immunity
Treatment Duration
Two doses in childhood for long-term immunity
Evidence Quality
HIGHNumber Needed to Harm (NNH)
1000000(Treat 1000000 patients to see 1 additional serious adverse event)
Confidence Score
98%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$70
Monitoring:$5
Side Effect Mgmt:$1
Total Annual:$76
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$1,000/QALY
QALYs Gained
0.5
Prescription Access Economics
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWMeasles, Mumps, and Rubella (MMR) Vaccine Outcomes
for Measles
Efficacy Outcomes
Overall Effectiveness
+97%
Common Side Effects
Fever
+15%
Mild rash
+5%
Temporary joint pain (adult women)
+25%
Swelling of glands in cheeks or neck
+1%
Serious allergic reaction
+0.0001%
Active Clinical Trials
2 active trials recruiting for Measles, Mumps, and Rubella (MMR) Vaccine in Measles
Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and Unrelated Infection in Children
NCT05758532RECRUITINGPHASE4
500 participants
INTERVENTIONAL
Geneva, Switzerland
Started: Mar 17, 2023
Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients
NCT07195032RECRUITINGPHASE4
60 participants
INTERVENTIONAL
Kansas City, United States
Started: Sep 11, 2025
Completed Clinical Trials
15 completed trials for Measles, Mumps, and Rubella (MMR) Vaccine in Measles
Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)
NCT01874457COMPLETED
150 participants
OBSERVATIONAL
Rio de Janeiro, Brazil
Started: May 1, 2008
Measles, Mumps, and Rubella (MMR) Immunity in College Students
NCT00962819COMPLETED
74 participants
OBSERVATIONAL
Decatur, United States
Started: Mar 1, 2010
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
NCT01777529COMPLETEDPHASE4
240 participants
INTERVENTIONAL
Rio de Janeiro, Brazil
Started: Oct 1, 2012
Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine
NCT03160820COMPLETEDPHASE4
873 participants
INTERVENTIONAL
Shijiazhuang, China +3 more
Started: Mar 1, 2016
Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
NCT06399003COMPLETEDPHASE3
1.2K participants
INTERVENTIONAL
Kisumu, Kenya
Started: Jun 28, 2024
Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines
NCT03368495COMPLETEDPHASE4
851 participants
INTERVENTIONAL
Eldorado, Argentina +3 more
Started: Nov 23, 2015
Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts
NCT03183765COMPLETEDPHASE4
48 participants
INTERVENTIONAL
Asyut, Egypt
Started: Aug 1, 2017
A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts
NCT04428359COMPLETEDNA
66 participants
INTERVENTIONAL
Dharān, Nepal
Started: Jun 1, 2020
Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine
NCT02880865COMPLETEDPHASE4
628 participants
INTERVENTIONAL
Manila, Philippines
Started: Oct 13, 2016
Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR)
NCT06331702COMPLETEDPHASE4
408 participants
INTERVENTIONAL
Nanjing, China
Started: Mar 2, 2024
Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers
NCT01188343COMPLETEDPHASE3
542 participants
INTERVENTIONAL
Taichung, Taiwan +2 more
Started: Aug 1, 2010
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
NCT01702428COMPLETEDPHASE3
5.02K participants
INTERVENTIONAL
Dothan, United States +89 more
Started: Nov 9, 2012
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
NCT03148990COMPLETEDPHASE2, PHASE3
432 participants
INTERVENTIONAL
Natal, Brazil +1 more
Started: Nov 20, 2018
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
NCT01991899COMPLETEDPHASE3
1.56K participants
INTERVENTIONAL
Belém, Brazil
Started: Feb 1, 2015
Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR
NCT02325310COMPLETEDPHASE4
14 participants
INTERVENTIONAL
Paris, France
Started: Feb 4, 2015
Showing 20 of 70 total trials